With the rapid progress in molecular biology, there is a great need to train academic surgical oncologists that can not only deliver state of the art surgical care, but can also lead multidisciplinary teams and research programs leveraging molecular oncology and new technologies. To address the national shortage of surgical investigators focused on surgical oncology, the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center has dedicated its T32 training program to producing academic surgical oncologists. The long-term objective is to train surgical residents and surgical oncology fellows in the essential research skills necessary to be productive independent surgical investigators, and leaders in surgical oncology. Moreover, we are committed to providing T32 training to groups that are underrepresented in academic surgical oncology, including minority individuals and women. Training is offered to postdoctoral M.D. or M.D. Ph.D. fellows either during a 24-month hiatus from general surgery residency training or during a three-year clinical/research fellowship in surgical oncology that begins after general surgery residency. Our T32 training program has been highly successful in achieving its goals and is now entering its 25th year. Upon completion of their residency training, most of our T32 research fellows either started fellowship training, or accepted academic surgical positions. Upon completion of their surgical oncology fellowship training, all of our T32 clinical/research fellows entered academic Surgical Oncology positions. Our T32 program provides research opportunities in a broad range of basic oncologic disciplines, including cancer biology, molecular oncology, cell signaling, nanotechnology, molecular therapeutics, biomarker development and validation, clinical trials, clinical effectiveness and outcomes research. This academic training program allows us to train surgeons with a diverse set of unique skills, increasing the likelihood of trainees obtaining an academic position upon completion of training. Training in biostatistics, and the responsible conduct of research, and a rich array of seminars and graduate courses are integral to this T32 program. The T32 program faculty includes established surgical investigators and full-time academic basic science researchers, all of whom have peer-reviewed grant support. Programs at the Texas Medical Center provide our trainees access to resources and potential collaborators at six academic institutions. Thus, the University of Texas MD Anderson Cancer Center is a highly stimulating environment for aspiring academic surgical oncologists.
With the rapid progress in molecular biology, there is a great need to train academic surgical oncologists that can not only deliver state of the art surgical care, but can also lead multidisciplinary teams as well as research programs leveraging molecular oncology and new technologies. The goal of this T32 training program is to train surgical trainees in the essential research skills necessary to be productive independent surgical investigators and leaders in surgical oncology.
|Bailey, Christina E; Tran Cao, Hop S; Hu, Chung-Yuan et al. (2015) Functional deficits and symptoms of long-term survivors of colorectal cancer treated by multimodality therapy differ by age at diagnosis. J Gastrointest Surg 19:180-8; discussio 188|
|Siroy, Alan E; Boland, Genevieve M; Milton, Denái R et al. (2015) Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol 135:508-15|
|Bailey, Christina E; Hu, Chung-Yuan; You, Y Nancy et al. (2015) Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg 150:17-22|
|Giza, Dana Elena; Vasilescu, Catalin; Calin, George A (2014) MicroRNAs and ceRNAs: therapeutic implications of RNA networks. Expert Opin Biol Ther 14:1285-93|
|Tran Cao, Hop S; Balachandran, Alpana; Wang, Huamin et al. (2014) Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg 18:269-78; discussion 278|
|Cruz-Monserrate, Zobeida; Roland, Christina L; Deng, Defeng et al. (2014) Targeting pancreatic ductal adenocarcinoma acidic microenvironment. Sci Rep 4:4410|
|Koay, Eugene J; Baio, Flavio E; Ondari, Alexander et al. (2014) Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol 11:065002|
|Chawla, Akhil; Philips, Anne V; Alatrash, Gheath et al. (2014) Immune checkpoints: A therapeutic target in triple negative breast cancer. Oncoimmunology 3:e28325|
|Suzuki, Rei; Kang, Ya'an; Li, Xinqun et al. (2014) Genistein potentiates the antitumor effect of 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells. Anticancer Res 34:4685-92|
|Mittendorf, Elizabeth A; Philips, Anne V; Meric-Bernstam, Funda et al. (2014) PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2:361-70|
Showing the most recent 10 out of 118 publications